Bob BeckmanExecutive Director, Clinical Research Oncology Daiichi-Sankyo
Joerg HeyerDirector, Cancer Biology AVEO
Vince O’NeillGlobal Head of Personalized Medicine & Companion Diagnostics sanofi aventis
Thomas WickhamVice President, Research & Development Merrimack
Lack of relevant predictive biomarkers, a complex library of advanced MDx techniques, uncertainty over effective trial design and execution…the road to successful MDx development is a complicated one.
Molecular Dx is your guide.
The 5th annual Molecular Dx: Cancer Drug Development will teach you how to apply the game changing techniques that are accelerating the development of personalized cancer treatment. Up to date clinical results and real-world case studies from your peers give you the clearest route to success in personalized cancer drug development.
2 conference streams allow you to truly personalize your agenda, to make sure you get the most out of the 2 days. One stream tackles the fundamentals of biomarker development and clinical trial optimization. The other focuses on the most up to date techniques driving MDx.
Successful Validation of NGS Tests for Molecular Diagnostics: A How-To-Guide
| FoundationOne is the first validated, pan-cancer, fully informative genomic profile for all solid tumors |  |
You will leave this workshop with the tangible evidence of the important role and clinical impact of NGS in cancer treatment, the guidance you need to validate your own test, and the know-how to overcome regulatory hurdles to gain approval of novel molecular testing systems.
